Published in J Natl Cancer Inst on September 20, 2006
Idiotypic Vaccination for Follicular Lymphoma Patients (FLIDVAX2006) | NCT00530140
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
The evolution of the danger theory. Interview by Lauren Constable, Commissioning Editor. Expert Rev Clin Immunol (2012) 1.87
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71
Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol (2014) 1.57
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol (2009) 1.46
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A (2008) 1.34
Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat Rev Cancer (2009) 1.17
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood (2009) 1.08
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol (2008) 1.04
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol (2012) 0.92
Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J Natl Cancer Inst (2006) 0.92
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Immunomodulation in the treatment of haematological malignancies. Clin Exp Med (2009) 0.87
A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther (2010) 0.85
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res (2011) 0.84
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant (2012) 0.84
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Lymphoma Immunotherapy: Current Status. Front Immunol (2015) 0.84
Immunotherapy in acute leukemia. Semin Hematol (2009) 0.82
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol (2008) 0.81
Cancer vaccines in old age. Exp Gerontol (2007) 0.81
Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol Immunother (2010) 0.81
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunol Immunother (2015) 0.81
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma. Biomed Res Int (2015) 0.80
Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol (2010) 0.79
Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders. PLoS One (2012) 0.77
Therapeutic vaccine for lymphoma. Yonsei Med J (2007) 0.77
Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. Am J Blood Res (2014) 0.77
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses. World J Clin Oncol (2011) 0.76
Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. J Biomed Biotechnol (2010) 0.76
Active immunotherapy: current state of the art in vaccine approaches for NHL. Curr Oncol Rep (2012) 0.75
Data mining of cancer vaccine trials: a bird's-eye view. Immunome Res (2008) 0.75
Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Hum Vaccin Immunother (2013) 0.75
Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait. Pharmaceuticals (Basel) (2010) 0.75
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. J Transl Med (2014) 0.75
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. World J Gastroenterol (2010) 0.75
Dendritic Cell Therapies for Hematologic Malignancies. Mol Ther Methods Clin Dev (2017) 0.75
Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol (2005) 11.05
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
RIFLE classification in patients with acute kidney injury in need of renal replacement therapy. Intensive Care Med (2007) 2.71
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest (2008) 2.18
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Causes for the intriguing presence of tRNAs in phages. Genome Res (2007) 1.93
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology (2003) 1.90
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood (2002) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
How essential are nonessential genes? Mol Biol Evol (2005) 1.63
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 1.61
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol (2014) 1.59
Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica (2005) 1.56
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J (2008) 1.52
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol (2010) 1.46
Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS (2005) 1.44
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
[Pharmacological alternatives to blood transfusion: what is new about?]. Med Clin (Barc) (2004) 1.39
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom (2010) 1.36
Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol (2007) 1.35
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica (2013) 1.32
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood (2004) 1.26
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood (2010) 1.26
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
The nature of circulating CD27+CD43+ B cells. J Exp Med (2011) 1.22
Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer (2003) 1.22
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol (2010) 1.22
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol (2009) 1.21
Conventional diagnostics in multiple myeloma. Eur J Cancer (2006) 1.20
Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem (2006) 1.19
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
Cancer development induced by graded expression of Snail in mice. Hum Mol Genet (2005) 1.18
Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A (2008) 1.16
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol (2009) 1.15
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood (2013) 1.15
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood (2013) 1.14
Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol (2011) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol (2009) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J (2012) 1.12
Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom (2010) 1.12
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count. Am J Clin Pathol (2013) 1.10
Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom (2007) 1.10
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica (2009) 1.08
Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol (2012) 1.07
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood (2003) 1.06
Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res (2007) 1.06
TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. Am J Pathol (2003) 1.05
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood (2003) 1.04
Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist (2007) 1.04
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica (2012) 1.04
Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica (2004) 1.04
Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom (2008) 1.03
Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol (2005) 1.03
A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03
Seasonal and spatial distribution of several endocrine-disrupting compounds in the Douro River Estuary, Portugal. Arch Environ Contam Toxicol (2008) 1.02
Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol (2013) 1.01
Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom (2004) 1.01
Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol (2011) 1.01
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer (2002) 1.01
Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis (2007) 1.01
Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01
Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells. Alcohol Clin Exp Res (2007) 1.01
Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol (2014) 1.00